Keros Therapeutics, Inc. announced changes to its Board of Directors (?Board?) and Executive Committee, effective July 1, 2024. Keros? Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024.

Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. Additionally, Christopher Rovaldi has been promoted to President, effective July 1, 2024.

Mr. Rovaldi succeeds Dr. Seehra, who served as the Company?s President from December 2015 until June 30, 2024. Mr. Rovaldi will also continue serving as Chief Operating Officer of Keros.